Charles McWherter, SVP & Chief Scientific Officer at CymaBay Therapeutics, Inc. (CBAY), bought 5,000 shares at $7.42 ($37K) on 2017-07-20, disclosed to the SEC on 2017-07-24.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.42 | 100 | $742 | 2.0% |
| 2 | $7.43 | 200 | $1K | 4.0% |
| 3 | $7.43 | 1,700 | $13K | 34.0% |
| 4 | $7.43 | 3,000 | $22K | 60.0% |
| Total | $7.43 avg | 5,000 | $37K | 100% |
| Filing → |
| CBAY | SELL | 2024-01-22 | $752K | — | Filing → |
| CBAY | SELL | 2023-12-18 | $487K | — | Filing → |
| CBAY | SELL | 2023-11-17 | $415K | — | Filing → |